This study showed that α2M was specifically upregulated in disease and its higher expression was associated with poorer kidney outcomes (Menon et al., 2020), suggesting the importance of α2M* signaling may also be relevant to non-diabetic kidney disease. The gene discussed is A2M; the disease is diabetic kidney disease.